Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Filament Health signs 3 new licenses and ships research doses for psilocybin drug PEX010 globally
TRIP
$14.61
+$0.61 +4.36%

Filament Health signs 3 new licenses and ships research doses for psilocybin drug PEX010 globally

Company Fundamentals
07 Apr 2026
Newsfile Corp
View Source
Bullish
pluang ai news

Filament Health, soon to be acquired by Red Light Holland, signed three new license agreements with institutions in Australia, the UK, and Canada for clinical research of its psilocybin drug candidate PEX010. The company also completed two research shipments to Canadian institutions for studies on cancer-related demoralization and treatment-resistant depression. These developments expand PEX010's global clinical network, highlighting growing demand for standardized botanical psilocybin in regulated research. The acquisition of Filament Health is pending shareholder and court approvals, aiming to strengthen Red Light Holland's position in the legal psychedelic sector.

More News (TRIP)

Longleaf Small-Cap Fund Q2 sees gains from real estate and travel, Boston Beer drags performance.

Longleaf Small-Cap Fund Q2 sees gains from real estate and travel, Boston Beer drags performance.

In Q2 2026, Longleaf Small-Cap Fund saw positive contributions from New York real estate firms Alexander’s and Empire State Realty Trust, as well as travel company Tripadvisor. However, Boston Beer negatively impacted the quarter due to mixed short-t...

Market News
Neutral
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App